Welcome to our dedicated page for Solana news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana stock.
Solana Company reports developments as a Nasdaq-listed company with a digital asset treasury dedicated to acquiring and holding Solana tokens (SOL) and a legacy neurotechnology medical-device business. News commonly covers SOL accumulation, staking rewards, NAV-per-share capital strategy, ATM and registered-direct equity financing, share repurchases, and financial results shaped by digital-asset fair value changes.
Company updates also describe institutional Solana infrastructure initiatives in Asia-Pacific, including validator and staking infrastructure, qualified-custody borrowing against natively staked SOL, and ecosystem partnerships with organizations such as Jito Foundation, Anchorage Digital, and Kamino.
Helius Medical Technologies (NASDAQ: HSDT) announced Breakthrough Designation for its PoNS™ device, aimed at treating gait deficits in Multiple Sclerosis patients. This designation allows expedited development and assessment by the FDA, with the goal of improving patient mobility through a non-drug treatment approach. The PoNS device is currently authorized in Canada and under investigation in the U.S. and other regions. The Breakthrough Devices Program facilitates timely access for critical medical devices while ensuring compliance with regulatory standards.
Helius Medical Technologies (HSDT) reported Q1 2020 financial results revealing a revenue decline to $0.2 million from $0.7 million in Q1 2019, driven primarily by decreased product sales of $191 thousand. The company experienced an operating loss of $4.0 million, a 41% improvement from the previous year. Net loss was $4.8 million, compared to a net income of $1.3 million in Q1 2019. Cash reserves decreased to $4.4 million as of March 31, 2020. Due to uncertainties from the COVID-19 pandemic, the full-year outlook has been withdrawn.
Summary not available.
Summary not available.